StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational Update

TORONTO, ON / ACCESSWIRE / May 17, 2024 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare company with the first and only mRNA multi-cancer diagnostic for screening for multiple, key cancers from a single sample of blood - Aristotle, and an oncologist-led adjunctive treatment protocol with early data - METRICS study - showing an improvement in outcome in cancer patients, announced its first quarter financial results for the three months ended March 31, 2024, and will provide an update on its business operations.

During the Quarter the Company achieved the following:

• Advanced conversations with multiple groups and partners:
• a new lab group in the US which will expand reach across both the US and Canada; focus is on both individual patients and employers.
• a new multi-center clinic group that will specifically offer Aristotle into Western Canada and the US.
• a large executive health group to offer multi-cancer screening via Aristotle
• Completed reorganization of the Richmond lab to maximize efficiencies post COVID-19 and ensure the focus is on Aristotle.
• Formalized Business Development in Europe to prepare for the launch of the COC Protocol 2.0.

Upcoming Catalysts for 2024

• New partnerships which focus on Aristotle.
• Care Oncology US expansion into the employer market.
• Care Oncology Europe launch of COC Protocol 2.0.
• Multiple Hospital Study with Aristotle in Greater Toronto Area.
• Glioblastoma Study in Europe.

Q1 2024 Financial Results

All amounts are expressed in U.S. dollars unless otherwise stated and results are reported in accordance with International Financial Reporting Standards.

The Company generated $0.523 million in cancer testing and treatment revenue for the three months ended March 31, 2024 as compared to revenue of $0.778 million for the three months ended March 31 2023 and realized a net loss of $0.386 million, or $0.00 basic and diluted loss per common share as compared to a $1.812 million net loss for the three months ended March 31, 2023, or $0.02 basic and diluted loss per common share.

		Three months ended March 31
		2024
(in thousands of US dollars, except per-share amounts)		$
Revenue
Total revenues			523
Direct costs			221
Gross profit			302
Gross Margin (%)			58

The Company's financial statements and management's discussion and analysis are available on www.sedar.com.